Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Depreciation and Depletion: 2012-2025

Historic Depreciation and Depletion for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to $161,917.

  • CorMedix's Depreciation and Depletion rose 535.97% to $161,917 in Q3 2025 from the same period last year, while for Sep 2025 it was $464,631, marking a year-over-year increase of 421.63%. This contributed to the annual value of $153,937 for FY2024, which is 117.56% up from last year.
  • As of Q3 2025, CorMedix's Depreciation and Depletion stood at $161,917, which was up 45.88% from $110,993 recorded in Q2 2025.
  • CorMedix's Depreciation and Depletion's 5-year high stood at $161,917 during Q3 2025, with a 5-year trough of $11,994 in Q1 2021.
  • Moreover, its 3-year median value for Depreciation and Depletion was $53,594 (2024), whereas its average is $69,213.
  • As far as peak fluctuations go, CorMedix's Depreciation and Depletion slumped by 75.15% in 2021, and later surged by 535.97% in 2025.
  • CorMedix's Depreciation and Depletion (Quarterly) stood at $20,047 in 2021, then increased by 12.32% to $22,516 in 2022, then dropped by 16.73% to $16,863 in 2023, then grew by 29.43% to $81,727 in 2024, then skyrocketed by 535.97% to $161,917 in 2025.
  • Its Depreciation and Depletion was $161,917 in Q3 2025, compared to $110,993 in Q2 2025 and $109,994 in Q1 2025.